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Background
PI3K/AKT pathway mutations are found in T-cell acute lymphoblastic leukemia, but their over-
all impact and associations with other genetic aberrations is unknown. PTEN mutations have
been proposed as secondary mutations that follow NOTCH1-activating mutations and cause
cellular resistance to γ-secretase inhibitors.
Design and Methods
The impact of PTEN, PI3K and AKT aberrations was studied in a genetically well-characterized
pediatric T-cell leukemia patient cohort (n=146) treated on DCOG or COALL protocols.   
Results
PTEN and AKT E17K aberrations were detected in 13% and 2% of patients, respectively.
Defective PTEN-splicing was identified in incidental cases. Patients without PTEN protein but
lacking exon-, splice-, promoter mutations or promoter hypermethylation were present.
PTEN/AKTmutations were especially abundant in TAL- or LMO-rearranged leukemia but near-
ly absent in TLX3-rearranged patients (P=0.03), the opposite to that observed for NOTCH1-
activating mutations. Most PTEN/AKT mutant patients either lacked NOTCH1-activating
mutations (P=0.006) or had weak NOTCH1-activating mutations (P=0.011), and consequently
expressed low intracellular NOTCH1, cMYC and MUSASHI levels. T-cell leukemia patients
without PTEN/AKT and NOTCH1-activating mutations fared well, with a cumulative inci-
dence of relapse of only 8% versus 35% for PTEN/AKT and/or NOTCH1-activated patients
(P=0.005). 
Conclusions
PI3K/AKT pathway aberrations are present in 18% of pediatric T-cell acute lymphoblastic
leukemia patients. Absence of strong NOTCH1-activating mutations in these cases may
explain cellular insensitivity to γ-secretase inhibitors.
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Introduction
Despite improved treatment outcome, children with T-
cell acute lymphoblastic leukemia (T-ALL) have a higher
relapse risk than children with B-lineage ALL.1 T-ALL is
characterized by mutually exclusive abnormalities in
TAL1, LMO2, TLX3/HOX11L2, TLX1/HOX11 or HOXA
oncogenes. Gene expression analyses supported the view
that the aberrations delineate specific T-ALL subgroups2-4
where cases with TAL1 or LMO2 aberrations share an
identical expression profile and may be considered to be a
single TALLMO subgroup.4,5 These abnormalities are
accompanied by other genetic aberrations, the so-called
type B mutations,6 that are found in nearly all subgroups.
These latter mutations include NOTCH1-activating muta-
tions affecting the NOTCH1 gene itself and/or inactivating
mutations in the F-Box WD40 domain containing protein
FBXW7 gene, which is a ubiquitin ligase that, apart from
NOTCH1, can also target various other molecules.7
NOTCH1-activating mutations have been observed in
more than 60% of T-ALL pediatric patients.8-14 We recently
observed that the incidence of NOTCH1-activating muta-
tions is higher for TLX3-rearranged patients while lower
for TAL- or LMO-rearranged patients.14 NOTCH1 is a
transmembrane receptor that is activated upon ligand
binding,15 and these mutations result in ligand independ-
ent activation.13 Various studies report different prognostic
consequences of NOTCH1-activating mutations.8-12,14,16-18
Recurrent mutations in the phosphatase and tensin
homolog (PTEN) gene were discovered in T-ALL patient
samples following common PTEN deletions in the triple
knockout mouse model (Terc, Atm and Trp53) that devel-
oped T-cell lymphomas19 as well as by a genome-wide
copy number analysis of ALL samples.20 PTEN mutations
were also observed in T-ALL cell lines,21-23 and analyses of
T-ALL patient samples revealed PTENmutations and dele-
tions in 5% and 15%, respectively.19 Palomero and co-
workers found an absence of PTEN expression in T-ALL
cell lines that were resistant to γ-secretase inhibitors (GSI).
Sequence analysis revealed PTEN mutations in 9 of 111
primary T-ALL samples, suggesting that PTEN mutations
that follow NOTCH1 mutations may provoke GSI resist-
ance.24 Various other studies showed a variable incidence
of PTEN mutations and/or deletions in T-ALL patients
(range 18-63%).10,25,26
PTEN acts downstream of the T-cell receptor and various
other pathways. It controls the PI3K/AKT pathway by
dephosphorylating PtdIns(3,4,5)P3 (PIP3) into PtdIns(3,4)P2
(PIP2). PI3-kinase (PI3K) has an opposite function and phos-
phorylates PIP2 into PIP3, which allows activation of AKT
via PDK1. PTEN-inactivating mutations result in an overac-
tive PI3K/AKT pathway.21,24 Few mutations are found in
PI3K and AKT1 genes themselves as alternative mecha-
nisms to activate AKT.26 Activated AKT can act on multiple
downstream targets that are involved in proliferation, cell
metabolism and apoptosis.27,28 One major downstream tar-
get is TSC2, which is repressed by AKT that, therefore,
facilitates protein synthesis through activation of mTOR.
The prognostic significance of an aberrantly activated
PI3K/AKT pathway by mutations in pediatric T-ALL is
fairly unknown.10,25,26 Also, PTEN, PI3K or AKT1 aberra-
tions in relation to NOTCH1-activating mutations are
unclear.10,24 We, therefore, investigated the incidence of
mono-allelic or bi-allelic PTEN-inactivating events and
PI3K or AKT1 aberrations in genetic subtypes of T-ALL,
their potential downstream effects, and their relationship
with clinical outcome.
Design and Methods
Patients’ samples 
A total of 146 primary pediatric T-ALL patients were included in
this study: 72 enrolled on the Dutch Childhood Oncology Group
(DCOG) protocols ALL-7/8 (n=30)29,30 or ALL-9 (n=42),31 and 74
patients enrolled on the German Co-Operative Study Group for
Childhood Acute Lymphoblastic Leukemia study (COALL-97,
n=74)12 with a median follow up of 67 and 52 months, respective-
ly. The patients’ parents or legal guardians provided informed con-
sent to use diagnostic patient biopsies for research in accordance
with the Institutional Review Board of the Erasmus MC
Rotterdam and the Declaration of Helsinki. Isolation of leukemia
cells was as previously described;32 all samples contained more
than 90% of leukemic blasts. Clinical and immunophenotypic
data were supplied by the study centers. Patients were classified
into T-cell development stages based on EGIL criteria, i.e. the pro-
/pre-T-cell subgroup (CD7+, CD2+ and/or CD5+ and/or CD8+, but
CD1- and sCD3-), the cortical T-cell (CD1+) or the mature T-cell
(sCD3+/CD1-) subgroup. Patients were identified as being positive
for a specific immunophenotypic marker when 25% or more of
leukemic blast stained positive for it. 
Statistical analysis
Statistical analysis was carried out using SPSS 15.0 software.
Pearson’s χ2 or Fisher’s exact tests were performed to test signifi-
cance levels for nominal data distributions, whereas the Mann-
Whitney U test was used for continuous data. Differences in
cumulative incidence of relapse (CIR), relapse free survival (RFS),
event free survival (EFS) or overall survival (OS) were tested by the
log rank test. An EFS event is defined as relapse, non-response to
induction therapy, toxicity related death or development of a sec-
ondary malignancy. P≤0.05 (two-sided) was considered statistical-
ly significant. In a comparison of DCOG and COALL cohorts, we
found no statistically significant differences between the distribu-
tion of age (P=0.508), male/female ratio (P=0.51), or distribution
according to genetic subtypes (P=0.395) excluding potential bias in
these cohorts. The 5-year EFS and OS rates for patients treated on
DCOG ALL-7/8 or ALL-9 protocols were similar: DCOG ALL-7/8
(n=30) versus DCOG ALL-9 (n=42) was 5-year EFS=67±9% versus
64±7%, 5-year OS was 70±8% versus 67±7%, and both DCOG
cohorts were regarded as a single treatment cohort. EFS and OS
rates for the German COALL-97 T-ALL cohort (n=74) were: 5-year
EFS=61±6%; 5-year OS=71±6%. A comparison of the impact of
specified factors on EFS, OS, RFS or CIR for combined DCOG and
COALL patient analyses was made in stratified analyses for the
DCOG or COALL protocol.
Results
Inactivating PTEN aberrations in pediatric 
T-ALL patients
To determine the prevalence of PTEN mutations, all 9
coding exons were amplified and sequenced, providing
data for 142 out of 146 pediatric T-ALL patients. Twenty-
seven mutations were identified in 16 patients (11%),
mostly representing heterozygous nonsense mutations
that truncate the PTEN protein (Figure 1A; Online
Supplementary Table S3). Ten patients had two mutations
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in single exons or distributed over different exons. Re-
sequencing of cloned PCR products revealed compound
heterozygous insertion mutations in 8 of 9 patients. One
patient (#1959) had two mutations that occurred in cis.
Most deletion/insertion mutations occured in exon 7,
truncating PTEN in the C2-domain. Other mutations were
detected in exons 5, 6 and 8. Two patients (#335 and
#9963) had missense mutations, of which the R129G
mutation had previously been shown to inactivate phos-
phatase activity.33
We also identified 4 patients who had intron mutations
located at the 3'-end in introns 1-2, 2-3 or 4-5. However,
amplification and sequencing of PTEN transcripts in these
patients revealed no alternative PTEN splice isoforms. 
High resolution array-CGH was performed on 113 of
146 pediatric T-ALL patients, and heterozygous PTEN
deletions were observed in 3 (#531, #8815 and #321;
Online Supplementary Table S3; Online Supplementary Figure
S1A). Loss of one PTEN allele in patient #531 explained its
homozygous mutation pattern. Patient #2486 had a
homozygous deletion of both PTEN alleles and since the
deleted areas were identical, homozygosity may be due to
uniparental disomy in this patient. Deletions could be val-
idated by FISH in 3 patients, except for patient #2486 for
whom there was a relatively small size of a homozygous
deletion of both PTEN alleles (Online Supplementary Figure
S1B). Array-CGH analysis also revealed subclonal dele-
tions in 2 PTEN-mutated patients (#344 and #1959) who
both carried two nonsense mutations affecting exons 5
and 7 (Online Supplementary Table S3; Online Supplementary
Figure S1C). Validation by FISH demonstrated copy loss in
40% of the leukemic blasts for patient #344, for whom
material was available (Online Supplementary Figure S1D).
Taken together, 19 of the 142 pediatric T-ALL patients
(13%) harbored inactivating PTEN aberrations, including
missense and nonsense mutations, as well as deletions of
the entire PTEN locus. Bi-allelic PTEN inactivation was
seen in 12 of 19 patients.
PTEN and AKT aberrations in pediatric T-ALL
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Figure 1. PTEN aberrations result in low PTEN expression in pediatric T-ALL patients. (A) Schematic representation of identified mutations in
the phosphatase- and C2-domains of the PTEN gene. Missense mutations are indicated by open triangles, whereas a silent mutation is pre-
sented as a filled gray triangle. Nonsense mutations due to insertions and/or deletions are indicated by a filled black triangle. (B) Total PTEN
and (C) phosphorylated PTEN (S380) expression levels in wild-type and PTEN-mutated pediatric T-ALL patient samples and T-ALL cell lines,
analyzed by reverse-phase protein microarray. Patients with a PTEN deletion are represented by a filled circle and patients with PTEN mis-
sense or nonsense mutations by an open circle. Wild-type patients that lack PTEN protein expression are indicated by a black square.
*Patient sample #335; this patient bears a PTEN R129G missense mutation.
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PTEN protein levels in relation to the PTEN
mutation status
Nonsense PTEN mutations result in loss of PTEN pro-
tein levels in T-ALL cell lines.19,24 Using reverse-phase pro-
tein microarray (RPMA), total PTEN protein levels as well
as phosphorylated (inactivated) PTEN protein levels
(S380) were quantified. PTENmutant T-ALL cell lines had
significantly lower PTEN and phosphorylated PTEN levels
than wild-type cell lines, and validated this technique
(Figure 1B and C; P=0.004 and P=0.004, respectively).
Material for RPMA analysis was available for 66 out of
146 T-ALL patient samples. Total PTEN (Figure 1B;
P<0.0001), as well as phosphorylated PTEN protein levels
(Figure 1C; P<0.0001), were significantly lower for
patients bearing inactivating PTENmutations. One PTEN-
mutated patient (#335) expressed PTEN protein (Figure 1B
and C) from the mutant allele carrying the missense
R129G mutation while the second allele was lost due to a
frameshift insertion in exon 5. PTEN protein levels were
absent or low in all other PTEN-mutated patients. PTEN
levels were significantly lower for bi-allelic affected
patients compared to mono-allelic affected patients
(Online Supplementary Figure S2; P=0.04). Some mono-allel-
ic-mutated/deleted patients had expression levels that
were comparable to bi-allelic patients, indicating that the
remaining wild-type allele in these patients may be
silenced through yet unknown mechanisms. In addition, 3
seemingly PTEN wild-type patient samples (#769, #8629
and #9243) and the PTEN wild-type cell line HPBALL
lacked PTEN protein (Figure 1B and C, black squares).
Array-CGH data were not available for these patients, but
large PTEN deletions were excluded by FISH analysis in 2
out of these 3 patients and HPBALL (data not shown). 
Defective PTEN-splicing in pediatric T-ALL patients
We then investigated whether absence of PTEN protein
in these 3 patients and HPBALL was due to splice defects,
mutations or hypermethylation of the PTEN promoter
region. In addition, we further investigated the 7 T-ALL
patients who seemed to have mono-allelic mutations or
deletions (#9160, #9919, #9963, #2759, #2852, #321 and
#8815). One of the 3 seemingly PTEN wild-type patients
(#9243) and 2 of 7 patients with mono-allelic PTENmuta-
tions (#2852 and #8815) demonstrated aberrant PTEN-
splicing and lacked expression of the full-length PTEN iso-
form (Figure 2; Online Supplementary Table S3). PCR-
sequence analysis for patient #9243 confirmed defective
splicing of exon 3 to exon 6, whereas intron 1-2 was defec-
tively spliced to exon 4 in patient #2852. Patient #8815
demonstrated defective PTEN exon 4 to exon 6 splicing
that eliminates the phosphatase domain. Miss-splicing,
therefore, provides an additional mechanism to eliminate
wild-type PTEN expression. So far, no explanation has
been found for defective PTEN-splicing as no mutations
were identified in the first 20-30 intronic bases flanking
acceptor/donor splice sites of affected exons. Defective
splicing in the absence of full-length PTEN transcript was
also observed in the mono-allelic PTEN-deleted cell line
LOUCY. 11 control T-ALL patient samples expressed the
PTEN wild-type isoform only (Figure 2, only 2 of 11
patients are shown). 
These 3 PTEN wild-type patients with reduced PTEN
expression, as well as these 7 PTEN mono-allelic-mutated
patients, were also investigated for PTEN promoter hyper-
methylation as a potential mechanism to silence wild-type
PTEN alleles. For this, methylation specific PCR (MSP)
was performed for the -1223 to -1032 region upstream rel-
ative to the transcriptional start site of PTEN (Online
Supplementary Figure S3A), in which hypermethylation has
been previously described in solid tumors and T-ALL.34-36
However, we found no evidence for PTEN promoter
hypermethylation (Online Supplementary Figure S3B and C).
We also found no evidence for deletions or mutations in
the PTEN promoter region (-1414 to -613bp) in any of
these T-ALL patients. 
PI3K/AKT pathway mutations in pediatric T-ALL
patients 
PTEN regulates the PI3K/AKT pathway, and inactiva-
tion of PTEN may result in constitutive activation of the
AKT pathway. Rare activating mutations in PI3K and AKT
have been described in T-ALL patient samples.26 To screen
for such mutations, exons 12 and 13 of PIK3RI (p85 regu-
latory subunit), and exon 10 of PIK3CA (p110 catalytic
subunit class IA) and exon 4 of AKT1 were amplified and
sequenced, and results were obtained for 135 of the 146 T-
ALL patients. No mutations were identified in PIK3RI or
PIK3CA. Three patients (2%) had a mutation in AKT1
changing glutamic acid into lysine at position 17 (E17K)
(Online Supplementary Table S3). This mutation has been
previously reported in a single T-ALL patient,26 and consti-
tutively activates AKT1.37
All AKT1-mutated patients lacked PTEN aberrations.
Overall, PTEN mutations or AKT1 mutations were identi-
fied in 25 of 142 pediatric T-ALL patients (18%), and were
called the PTEN/AKT mutant patient group. This group
also included both PTEN wild-type patients who lacked
PTEN protein expression (#769 and #8629). Based on our
findings and those reported in the literature,19,24 more than
half of T-ALL cell lines have inactivated PTEN (Online
Supplementary Table S4).
Comparing the activation status of AKT and potential
downstream signaling molecules in PTEN/AKT-mutated
versuswild-type patients using RPMA, we did not observe
any difference in phosphorylated AKT (Ser473 and
Thr308) levels, nor in the phosphorylated status of down-
stream AKT targets including mTOR, p70 S6 kinase, 4E-
BP1, TSC2, PRAS40 and FOXO1 (Online Supplementary
Figure S4A and B). As AKT activation has also been
described as downstream protein of the NOTCH1 path-
way,24,38 we distinguished between PTEN/AKT mutant
patients, NOTCH1-activated and patients lacking
PTEN/AKT or NOTCH1/FBXW7 mutations; we did not
identify any significant differences in phosphorylated
AKT levels or downstream AKT targets (data not shown).
PTEN/AKT aberrations in relation to biological, clinical
and molecular-cytogenetic parameters 
PTEN/AKT mutations were not associated with gender
(P=0.97) or white blood cell counts (P=0.61), but seemed
to be associated with younger age (Table 1; P=0.05). 
Eight of 25 PTEN/AKT patients had TAL1 rearrange-
ments (Table 1; Online Supplementary Table S5; P=0.05),
whereas only 3 of 25 PTEN/AKT patients had TLX1 or
TLX3 rearrangements (1 TLX3- and 2 TLX1-rearranged
patients; P=0.003). Similar associations were observed for
PTEN-mutated patients only. For T-ALL clusters based on
unsupervized gene expression profiling,5 we noticed that
PTEN/AKT mutations were predominantly present in
TAL/LMO cluster patients although this was not signifi-
L. Zuurbier et al.
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cant, while the incidence of these mutations was signifi-
cantly lower for the TLX cluster that comprises most
TLX3- and HOXA-rearranged cases (P=0.002). No associa-
tions were observed with PHF6 or WT1 mutations nor
with CDKN2A/B deletions; this is in line with previous
findings as reported by Gutierrez et al.26
Initially, PTEN mutations were suggested to be second-
ary mutations following NOTCH1-activating mutations,
rendering cells insensitive to γ-secretase inhibitors.24 We,
therefore, compared the distribution of PTEN/AKT muta-
tions with that of NOTCH1-activating mutations.
NOTCH1-activating mutations (in NOTCH1 and/or
FBXW7) were present in 63% of the patients.14 Strikingly,
patients carrying NOTCH1-activating mutations seemed
to have a lower incidence of PTEN/AKT aberrations as
only 10 of 90 NOTCH1/FBXW7-mutated patients carried
PTEN/AKT aberrations, in contrast to 15 of 51
NOTCH1/FBXW7 wild-type patients (Table 1; P=0.006).
Remarkably, PTEN/AKT-mutated patients who had
NOTCH1/FBXW7 mutations, in particular harbored weak
NOTCH1-activating mutations only (9 of 10 cases;
P=0.011).14,39
So NOTCH1-activating mutations and PTEN/AKT
mutations seem to be hits that are associated with differ-
ent molecular cytogenetic T-ALL subgroups.14 This, seems
to be further strengthened by our RPMA analyses that
showed that PTEN/AKTmutant patients have low expres-
sion of intracellular NOTCH1 (ICN; P=0.003), cMYC, as a
prime NOTCH1-target gene24,40 (P=0.01) and
MUSASHI1/2 (MSI1/2; Online Supplementary Figure S4C;
P=0.002) which is a repressor of the NOTCH1 negative
regulator NUMB.41 This is different in T-ALL cell lines, as
10 of 13 PTEN/AKT-mutated cell lines also harbor
NOTCH1-activating mutations (Online Supplementary
Table S4).
We then investigated whether PTEN/AKTmutations are
associated with resistance to γ-secretase inhibitors as pre-
viously suggested.24 For this purpose, we measured the
G1-arrest in a large panel of T-ALL cell lines following γ-
secretase inhibitor treatment. Various cell lines (JURKAT,
P12Ichikawa, PF382, MOLT16 and KARPAS45) that had
PTEN-inactivating mutations (Online Supplementary Table
S4) were resistant to γ-secretase inhibitor treatment
(Online Supplementary Figure S5A).24 But four cell lines with
PTEN-inactivating aberrations (SKW3, SUPT1, LOUCY,
KE37) rapidly underwent G1-arrest following treatment.
So, PTEN loss-of-function mutations are not necessarily
associated with resistance towards γ-secretase inhibitors.
All PTEN mutant lines lacked PTEN protein expression
regardless of their γ-secretase inhibitor response, with the
exception of SUPT1 and RPMI8402 that had PTEN mis-
sense mutations (Online Supplementary Figure S5B).
Good outcome for T-ALL patients lacking PTEN/AKT
and/or NOTCH1/FBXW7 aberrations
In relation to outcome, there was no difference in
relapse free survival (RFS) and event free survival (EFS)
rates between PTEN/AKT mutant patients and wild-type
patients (Online Supplementary Figures S6A and B). In con-
trast to previous observations,25,26 no differences in out-
come for PTEN-deleted patients versus other patients were
observed, nor for patients having mono-allelic versus bi-
allelic PTENmutations (data not shown). As the PTEN/AKT
wild-type patient group is enriched for patients who har-
bor NOTCH1-activating mutations, which were previous-
ly associated with a trend towards poor outcome,14 we
compared CIR and EFS rates for patients with PTEN/AKT
aberrations and/or NOTCH1-activating mutations versus
patients lacking these mutations (wild-type patients).
Wild-type patients had a significantly lower 5-year CIR
rate (8%) than PTEN/AKT and/or NOTCH1-activated
patients (35%) in a stratified analysis in our cohorts
(Figure 3A and Online Supplementary S6B; P=0.005). Only 2
of 36 wild-type patients relapsed versus 33 of 105 patients
who had NOTCH1-activating and/or PTEN/AKT muta-
tions (Online Supplementary Table S6; P=0.002). The 5-year
EFS rate for wild-type patients was 75±7.7% versus
60±5.0% for NOTCH1/FBXW7 and/or PTEN/AKTmutant
patients (Figure 3B; P=0.15), due to a relatively high num-
ber of toxic deaths or secondary malignancies in the wild-
type patient group (Online Supplementary Table S6; P=0.03;
Online Supplementary Figure S6B). We further investigated
clinical and molecular-genetic parameters with 5-year
relapse free survival (RFS) rates (Online Supplementary Table
S7). We found improved 5-year RFS rates for male patients
(P=0.01), but inferior RFS rates for TLX3-rearranged T-ALL
PTEN and AKT aberrations in pediatric T-ALL
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Figure 2. Defective splicing of PTEN transcripts. Analysis of alternative PTEN splicing in 2 wild-type PTEN patients and PTEN expression (#419
and #914), seven PTEN wild-type patients and cell lines without PTEN expression (#768, #8628, #9243, HPBALL, LOUCY, HSB2 and KE37),
5 patients with silent or intronic mutations (#2720, #2698, #2845, #2790 and #540) and 7 patients with mono-allelic PTEN mutations or
deletions (#9160, #9919, #9963, #2759, #2852, #321 and #8815). RT-PCR I covers wild-type and alternative PTEN transcripts from exon
1 through exon 6, whereas RT-PCR II covers wild-type and alternative PTEN transcripts from exon 6 through 9. *Patients and cell lines
expressing aberrant transcripts.
©F
err
ata
 S
tor
ti F
ou
nd
ati
on
(P=0.04) as well as for patients having PTEN/AKT and/or
NOTCH1-activating mutations (P=0.005). Multivariate
analysis demonstrated that male gender and
PTEN/AKT/NOTCH1/FBXW7 mutations remained inde-
pendent predictors for improved or worse outcome,
respectively (Online Supplementary Table S8).
Discussion
In our pediatric T-ALL patient cohort (n=146), 18% of
the patients have aberrations that affect the PI3K/AKT
pathway. PTEN aberrations were identified in approxi-
mately 16%, whereas AKT mutations were observed in
L. Zuurbier et al.
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Table 1. Overall clinical, immunophenotypic and molecular cytogenetic characteristics of PTEN or PTEN/AKT-mutated patients versus wild-type patients.
PTEN mutation /deletion PTEN or AKT mutation/deletion +
patients with a low PTEN protein
expression (PTEN/AKT)
Clinical (n=142) WT Mut P □ WT Mut P □
Gender 0.60 0.97
Male 85 12 80 17
Female 38 7 37 8
Median age (range) 7.8 (1.1-17.8) 4.3 (2.2-15.9) 7.9 (1.1-17.8) 4.9 (2.2-15.9) 0.05†
Median WBC (range) 120 (2-900) 136 (5-600) 120 (2-900) 136 (5-600) 0.61†
Cytogenetics (n=142) WT n (%) Mut n (%) P □ WT n (%) Mut n (%) P □
TAL1+ (n=26) 20 (77) 6 (23) 0.11 18 (69) 8 (31) 0.05
LMO2+ (n=14) 13 (93) 1 (7) 0.69‡ 13 (93) 1 (7) 0.46‡
TLX3+ (n=28) 28 (100) 0 (0) 0.03‡ 27 (96) 1 (4) 0.03‡
TLX1+ (n=7) 6 (86) 1 (14) 1‡ 5 (71) 2 (29) 0.61‡
HOXA+ (n=13) 13 (100) 0 (0) 0.22‡ 13 (100) 0 (0) 0.13‡
§MEF2C+ (n=6) 5 (83) 1 (17) 0.81 5 (83) 1 (17) 1‡
§NKX2-1+ (n=6) 5 (83) 1 (17) 0.81 5 (83) 1 (17) 1‡
Unknown (n=42) 33 (79) 9 (21) 0.07 31 (74) 11 (25) 0.08
Gene expression WT n (%) Mut n (%) P □ WT n (%) Mut n (%) P □
clusters (n=113)ǁ
TAL/LMO+ (n=51) 41 (80) 10 (20) 0.07 38 (75) 13 (25) 0.09
TLX+ (n=28) 28 (100) 0 (0) 0.02‡ 28 (100) 0 (0) 0.002‡
Proliferative+ (n=19) 16 (84) 3 (16) 0.72‡ 13 (68) 6 (32) 0.11
Immature/(ETP-ALL)+ (n=15) 13 (87) 2 (13) 1.0‡ 13 (87) 2 (13) 0.73‡
NOTCH1/FBXW7 WT n (%) Mut n (%) P □ WT n (%) Mut n (%) P □
status (n=141)
Wild-type (n=51) 39 (76) 12 (24) 0.008 36 (71) 15 (29) 0.006
Mutant (n=90) 83 (92) 7 (8) 80 (89) 10 (11)
Wild-type (n=51) 39 (76) 12 (24) 0.02‡ 36 (71) 15 (29) 0.011‡
¶Weak activating mutation (n=62) 56 (90) 6 (10) 53 (85) 9 (15)
#Strong activating mutation (n=28) 27 (96) 1 (4) 27 (96) 1 (4)
PHF6 status (n=62) WT n (%) Mut n (%) P □ WT n (%) Mut n (%) P □
Mutant 11 (100) 0 (0) 0.33‡ 10 (91) 1 (9) 0.67‡
Wild-type 44 (86) 7 (14) 42 (82) 9 (18)
WT1 status (n=142) WT n (%) Mut n (%) P □ WT n (%) Mut n (%) P □
Mutant 16 (100) 0 (0) 0.13‡ 14 (88) 2 (12) 0.74‡
Wild-type 107 (85) 19 (15) 103 (82) 23 (18)
Del9p21 status (n=112) WT n (%) Mut n (%) P □ WT n (%) Mut n (%) P □
Mutant 73 (84) 14 (16) 0.52‡ 72 (83) 15 (17) 0.76‡
Wild-type 23 (92) 2 (8) 22 (88) 3 (12)
Significant P values are indicated in bold; all P values were calculated by using Pearson's χ2 test, unless indicated otherwise; WT: wild-type; Mut: mutant; P: P value; □statistical analysis of the
frequency of PTEN or PTEN/AKT aberrations for specific genetic T-ALL subgroups indicated compared to all other T-ALL subgroups combined; Median age indicated in years; WBC: white blood
cell count; white blood cell counts are indicated as number of blasts (x109/L); †Mann-Whitney-U test; ‡Fisher's exact test; §Different genetic aberrations have been identified that all result in
the activation of the MEF2C or NKX2-1/NKX2-2 oncogenes that define novel genetic T-ALL subtypes;5││, 113 out of 117 T-ALL patients included in the gene expression profiling study5 had
a known PTEN and AKT mutation status. T-ALL patients were assigned to clusters based on unsupervized gene expression cluster analysis.5 The TAL/LMO group is based on the presence of
TAL1 or LMO2 rearrangements or by having a TAL/LMO expression signature;5 ¶Weak NOTCH1 activating mutations are considered as mutations in the NOTCH1 heterodimerization (HD)
domain or NOTCH1 PEST domain or in FBXW7;39 #Strong NOTCH1 activating mutations are considered as mutations in the juxtamembrane (JM) or mutations in the NOTCH1 HD domain
in combination with mutations in the NOTCH1 PEST domain or FBXW7W7.39
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approximately 2% of T-ALL patients. In other studies,
PTEN mutations were identified in 5-27% of
patients.10,19,24-26 Gutierrez et al.26 identified PTEN/AKT
mutations in approximately 48% of the patients (n=44),
which is considerably higher than in our study.
Major PTEN inactivation mechanisms are non-
sense mutations and deletions. We identified defective
splicing as an alternative mechanism to reduce PTEN
expression in 2% of T-ALL patients. No mutations in
donor/acceptor sites or closely flanking intronic sequences
of the exons involved were identified, but we cannot
exclude that intronic mutations at a greater distance from
these donor/acceptor sites could be present that affect
PTEN-splicing. Splice-defective patients did not express
full-length PTEN transcript, indicating that both PTEN
alleles were inactivated. Alternative splice isoforms of
PTEN have been described before in Cowden Syndrome
(CS), sporadic breast cancer or Bannayan-Riley-Ruvalcaba
syndrome (BRRS), and were shown to alter full-length
PTEN expression levels.42 Two PTEN wild-type T-ALL
patients completely lacked PTEN protein. Although PTEN
promoter mutations have been described for patients with
CS and autism spectrum disorders,43,44 and PTEN promoter
hypermethylation was described for endometrial cancer,
sporadic breast cancer and T-ALL,34-36 there was no evi-
dence of promoter mutations or promoter hypermethyla-
tion in our T-ALL patient series, so there may be addition-
al mechanisms to inactivate PTEN in T-ALL. We cannot
exclude the possibility that these mechanisms involve
microRNAs, including miR-19b or miR-20a.45 Also, a regu-
latory role for the PTEN pseudogene PTENP1 on PTEN
expression has been identified before, with PTENP1 acting
as a decoy transcript that binds miR-19b and miR-20a,
resulting in elevated PTEN levels.45 Other miRNAs have
been identified that regulate PTEN expression.8
Mono-allelic inactivation of PTEN in cancer led to the
hypothesis that PTEN is a haploinsufficient tumor sup-
pressor gene.46 We identified PTEN aberrations in a single
allele in approximately one-third of PTEN-mutated T-ALL
patients, and these patients expressed lower PTEN protein
levels compared to wild-type patients, in agreement with
previous findings.24 These expression levels were still sig-
nificantly higher than in patients with bi-allelic PTEN
mutations/deletions. Thus, mono-allelic loss of PTEN may
be sufficient to provide a proliferation advantage in T-ALL,
but there is still oncogenic pressure to inactivate the sec-
ond functional PTEN allele. This is further substantiated
by subclonal PTEN deletions in 2 T-ALL patients who
already had one dysfunctional PTEN allele. 
Inactivation of PTEN results in ectopic activation of
AKT.19,24 However, using RPMA, we found no difference in
phospho-AKT levels or phosphorylation of downstream
AKT targets between PTEN/AKT mutant patients and
patients lacking PTEN/AKT aberrations, and there were
also no differences observed between PTEN/AKT mutant
cell lines and wild-type lines. Possibly, differences in phos-
phorylation levels for AKT and downstream targets
between PTEN/AKT mutant patients and wild-type
patients are very subtle and difficult to identify on primary
patient material by RPMA; AKT may also be regulated
through other oncogenic pathways. In this respect, activa-
tion of the AKT pathway has been identified in over 75%
of T-ALL cases;47 this is well above the incidence of
PTEN/AKT aberrations seen in this study. In T-ALL, acti-
vation of AKT has been described downstream of
NOTCH138 and AKT may be activated upon transcription-
al repression of PTEN by the NOTCH1-activated tran-
scriptional repressor HES1.24 So AKT activation as a conse-
quence of PTEN/AKT mutations or through NOTCH1-
activating mechanisms could explain the lower frequency
of PTEN/AKT mutations in patients who have NOTCH1-
activating mutations in our cohort. Furthermore, the 9 of
10 PTEN/AKT-mutated patients who had NOTCH1-acti-
vating mutations, only had weakly NOTCH1-activating
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Figure 3. T-ALL patients without PTEN/AKT and/or NOTCH1-activating mutations have a good outcome. Cumulative incidence of relapse (CIR)
(A) and event-free survival (EFS) (B) for DCOG and COALL pediatric T-ALL patients. Different patient groups are indicated in the legend. Log
rank P values in a stratified analysis for DCOG and COALL protocols have been indicated for indicated mutation groups relative to PTEN/AKT
and NOTCH1/FBXW7 non-mutated patients (i.e. wild-type patients).
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mutations (i.e. NOTCH1-HD or PEST domain mutations
or FBXW7 mutations),39 pointing to a common down-
stream target and, therefore, removing the need to accu-
mulate both PTEN/AKT and strong NOTCH1-activating
mutations. Also, in the study of Medyouf et al.,48 4 of the
6 primary T-ALL samples with PTEN-inactivating muta-
tions were also NOTCH1-mutated and only carried weak-
ly activating PEST domain mutations. Consequently, ICN,
MYC (another NOTCH1 target gene) and the indirect
NOTCH1 activator MUSASHI1/2 are expressed at lower
levels in PTEN/AKT-mutated patients. PTEN/AKT muta-
tions and NOTCH1-activating mutations may both con-
verge on the activation of AKT. However, the associations
of PTEN/AKT mutations with TAL/LMO-rearranged
patients seen in this study and NOTCH1-activating muta-
tions that are especially predominant in TLX3-rearranged
patients14 also imply that both oncogenic pathways may
activate different routes within different T-ALL subtypes. 
The lower frequency of combined PTEN/AKT and
NOTCH1-activating mutations may further explain cellu-
lar insensitivity of PTEN/AKTmutant cases towards γ-sec-
retase inhibitors (GSI).24 Our data show that most PTEN-
inactivating mutations occur independently of NOTCH1-
activating mutations, implying that PTEN/AKT-mutant
leukemic cells are not sensitive towards GSIs rather than
that PTEN aberrations would provoke γ-secretase resist-
ance.24 In this respect, we demonstrated that various T-
ALL cell lines that have PTEN mutations (SKW3, SUPT1,
LOUCY and KE37) respond to γ-secretase inhibitors. Our
findings are in agreement with one previous study that
showed that PTEN negative primary T-ALL cells or
NOTCH1-induced T-ALL cells in mice on a Pten null back-
ground are as sensitive to γ-secretase inhibitors as primary
T-ALL cells or NOTCH-induced tumors with unaffected
PTEN loci, respectively.48
In the study of Gutierrez et al.,26 PTEN/AKT-mutated
patients did not predict for event free survival, but PTEN
deletions seemed to be associated with early treatment
failure. Jotta et al.25 demonstrated poor overall survival
rates for PTEN-mutated high-risk patients. In this last
study, a trend towards poor outcome was related to the
presence of mono-allelic or bi-allelic PTEN
mutations/deletions. We could not confirm this, as most
of our patients demonstrated bi-allelic inactivation of
PTEN through additional mechanisms, such as alternative
splicing that has so far not been investigated in T-ALL.
Distinguishing patient groups in our cohort based on the
presence or absence of PTEN/AKT and NOTCH1/FBXW7
mutations revealed that patients with PTEN/AKT muta-
tions fared as poorly as patients with NOTCH1/FBXW7
mutations or both. The patients without PTEN/AKT and
NOTCH1/FBXW7 mutations had a good outcome, and
almost no relapses were observed. 
In conclusion, missense or nonsense mutations or dele-
tions affecting the PTEN gene occur in 13% of pediatric T-
ALL patients, and may result in the activation of the AKT
pathway. The AKT E17K activating mutation was
observed in approximately 2% of T-ALL patients.
Defective PTEN-splicing is an additional PTEN-inactivat-
ing event, but the underlying mechanism is still not fully
understood. PTEN/AKT mutations are predominantly
associated with TAL/LMO-rearranged T-ALL, with most
PTEN/AKT-mutated patients lacking NOTCH1-activating
mutations. T-ALL patients who lack PTEN/AKT and
NOTCH1/FBXW7mutations demonstrated a good overall
outcome.
Authorship and Disclosures
The information provided by the authors about contributions from
persons listed as authors and in acknowledgments is available with
the full text of this paper at www.haematologica.org.
Financial and other disclosures provided by the authors using the
ICMJE (www.icmje.org) Uniform Format for Disclosure of
Competing Interests are also available at www.haematologica.org.
L. Zuurbier et al.
1412 haematologica | 2012; 97(9)
References
1. Pui CH, Evans WE. Treatment of acute lym-
phoblastic leukemia. N Engl J Med. 2006;354
(2):166-78.
2. Ferrando AA, Neuberg DS, Staunton J, Loh
ML, Huard C, Raimondi SC, et al. Gene
expression signatures define novel oncogenic
pathways in T cell acute lymphoblastic
leukemia. Cancer Cell. 2002;1(1):75-87.
3. Soulier J, Clappier E, Cayuela JM, Regnault
A, Garcia-Peydro M, Dombret H, et al.
HOXA genes are included in genetic and bio-
logic networks defining human acute T-cell
leukemia (T-ALL). Blood. 2005;106(1):274-
86.
4. Van Vlierberghe P, van Grotel M, Tchinda J,
Lee C, Beverloo HB, van der Spek PJ, et al.
The recurrent SET-NUP214 fusion as a new
HOXA activation mechanism in pediatric T-
cell acute lymphoblastic leukemia. Blood.
2008;111(9):4668-80.
5. Homminga I, Pieters R, Langerak AW, de
Rooi JJ, Stubbs A, Verstegen M, et al.
Integrated Transcript and Genome Analyses
Reveal NKX2-1 and MEF2C as Potential
Oncogenes in T Cell Acute Lymphoblastic
Leukemia. Cancer Cell.19(4):484-97.
6. Meijerink JP. Genetic rearrangements in rela-
tion to immunophenotype and outcome in
T-cell acute lymphoblastic leukaemia. Best
Pract Res Clin Haematol. 2010;23(3):307-18.
7. Mullighan CG. Mutations of NOTCH1,
FBXW7, and prognosis in T-lineage acute
lymphoblastic leukemia. Haematologica.
2009;94(10):1338-40.
8. Clappier E, Collette S, Grardel N, Girard S,
Suarez L, Brunie G, et al. NOTCH1 and
FBXW7 mutations have a favorable impact
on early response to treatment, but not on
outcome, in children with T-cell acute lym-
phoblastic leukemia (T-ALL) treated on
EORTC trials 58881 and 58951. Leukemia.
2010;24(12):2023-31.
9. Kox C, Zimmermann M, Stanulla M, Leible
S, Schrappe M, Ludwig WD, et al. The favor-
able effect of activating NOTCH1 receptor
mutations on long-term outcome in T-ALL
patients treated on the ALL-BFM 2000 proto-
col can be separated from FBXW7 loss of
function. Leukemia. 2010;24(12):2005-13.
10. Larson Gedman A, Chen Q, Kugel
Desmoulin S, Ge Y, LaFiura K, Haska CL, et
al. The impact of NOTCH1, FBW7 and
PTEN mutations on prognosis and down-
stream signaling in pediatric T-cell acute lym-
phoblastic leukemia: a report from the
Children's Oncology Group. Leukemia.
2009;23(8):1417-25.
11. Park MJ, Taki T, Oda M, Watanabe T,
Yumura-Yagi K, Kobayashi R, et al. FBXW7
and NOTCH1 mutations in childhood T cell
acute lymphoblastic leukaemia and T cell
non-Hodgkin lymphoma. Br J Haematol.
2009;145(2):198-206.
12. van Grotel M, Meijerink JP, van Wering ER,
Langerak AW, Beverloo HB, Buijs-Gladdines
JG, et al. Prognostic significance of molecu-
lar-cytogenetic abnormalities in pediatric T-
ALL is not explained by immunophenotypic
differences. Leukemia. 2008;22(1):124-31.
13. Weng AP, Ferrando AA, Lee W, Morris JP 4th,
Silverman LB, Sanchez-Irizarry C, et al.
Activating mutations of NOTCH1 in human
T cell acute lymphoblastic leukemia. Science.
2004;306(5694):269-71.
14. Zuurbier L, Homminga I, Calvert V, te
Winkel ML, Buijs-Gladdines JG, Kooi C, et
al. NOTCH1 and/or FBXW7 mutations pre-
dict for initial good prednisone response but
not for improved outcome in pediatric T-cell
acute lymphoblastic leukemia patients treat-
ed on DCOG or COALL protocols.
Leukemia. 2010;24(12):2014-22.
15. Aster JC, Pear WS, Blacklow SC. Notch sig-
naling in leukemia. Annu Rev Pathol.
©F
err
ata
 S
tor
ti F
ou
nd
io
2008;3:587-613.
16. Asnafi V, Buzyn A, Le Noir S, Baleydier F,
Simon A, Beldjord K, et al.
NOTCH1/FBXW7 mutation identifies a
large subgroup with favorable outcome in
adult T-cell acute lymphoblastic leukemia (T-
ALL): a Group for Research on Adult Acute
Lymphoblastic Leukemia (GRAALL) study.
Blood. 2009;113(17):3918-24.
17. Breit S, Stanulla M, Flohr T, Schrappe M,
Ludwig WD, Tolle G, et al. Activating
NOTCH1 mutations predict favorable early
treatment response and long-term outcome
in childhood precursor T-cell lymphoblastic
leukemia. Blood. 2006;108(4):1151-7.
18. Zhu YM, Zhao WL, Fu JF, Shi JY, Pan Q, Hu
J, et al. NOTCH1 mutations in T-cell acute
lymphoblastic leukemia: prognostic signifi-
cance and implication in multifactorial leuke-
mogenesis. Clin Cancer Res. 2006;12(10):
3043-9.
19. Maser RS, Choudhury B, Campbell PJ, Feng
B, Wong KK, Protopopov A, et al.
Chromosomally unstable mouse tumours
have genomic alterations similar to diverse
human cancers. Nature. 2007;447(7147):966-
71.
20. Mullighan CG, Goorha S, Radtke I, Miller
CB, Coustan-Smith E, Dalton JD, et al.
Genome-wide analysis of genetic alterations
in acute lymphoblastic leukaemia. Nature.
2007;446(7137):758-64.
21. Shan X, Czar MJ, Bunnell SC, Liu P, Liu Y,
Schwartzberg PL, et al. Deficiency of PTEN
in Jurkat T cells causes constitutive localiza-
tion of Itk to the plasma membrane and
hyperresponsiveness to CD3 stimulation.
Mol Cell Biol. 2000;20(18):6945-57.
22. Sakai A, Thieblemont C, Wellmann A, Jaffe
ES, Raffeld M. PTEN gene alterations in lym-
phoid neoplasms. Blood. 1998;92(9):3410-5.
23. Gronbaek K, Zeuthen J, Guldberg P, Ralfkiaer
E, Hou-Jensen K. Alterations of the
MMAC1/PTEN gene in lymphoid malignan-
cies. Blood. 1998;91(11):4388-90.
24. Palomero T, Sulis ML, Cortina M, Real PJ,
Barnes K, Ciofani M, et al. Mutational loss of
PTEN induces resistance to NOTCH1 inhibi-
tion in T-cell leukemia. Nat Med. 2007;13
(10):1203-10.
25. Jotta PY, Ganazza MA, Silva A, Viana MB, da
Silva MJ, Zambaldi LJ, et al. Negative prog-
nostic impact of PTEN mutation in pediatric
T-cell acute lymphoblastic leukemia.
Leukemia. 2010;24(1):239-42.
26. Gutierrez A, Sanda T, Grebliunaite R,
Carracedo A, Salmena L, Ahn Y, et al. High
frequency of PTEN, PI3K, and AKT abnor-
malities in T-cell acute lymphoblastic
leukemia. Blood. 2009;114(3):647-50.
27. Leslie NR, Downes CP. PTEN function: how
normal cells control it and tumour cells lose
it. Biochem J. 2004;382(Pt 1):1-11.
28. Maehama T. PTEN: its deregulation and
tumorigenesis. Biol Pharm Bull. 2007;30(9):
1624-7.
29. Kamps WA, Bokkerink JP, Hahlen K,
Hermans J, Riehm H, Gadner H, et al.
Intensive treatment of children with acute
lymphoblastic leukemia according to ALL-
BFM-86 without cranial radiotherapy: results
of Dutch Childhood Leukemia Study Group
Protocol ALL-7 (1988-1991). Blood. 1999;94
(4):1226-36.
30. Kamps WA, Bokkerink JP, Hakvoort-
Cammel FG, Veerman AJ, Weening RS, van
Wering ER, et al. BFM-oriented treatment for
children with acute lymphoblastic leukemia
without cranial irradiation and treatment
reduction for standard risk patients: results of
DCLSG protocol ALL-8 (1991-1996).
Leukemia. 2002;16(6):1099-111.
31. Veerman AJ, Kamps WA, van den Berg H,
van den Berg E, Bokkerink JP, Bruin MC, et al.
Dexamethasone-based therapy for child-
hood acute lymphoblastic leukaemia: results
of the prospective Dutch Childhood
Oncology Group (DCOG) protocol ALL-9
(1997-2004). Lancet Oncol. 2009;10(10):957-
66.
32. Van Vlierberghe P, van Grotel M, Beverloo
HB, Lee C, Helgason T, Buijs-Gladdines J, et
al. The cryptic chromosomal deletion
del(11)(p12p13) as a new activation mecha-
nism of LMO2 in pediatric T-cell acute lym-
phoblastic leukemia. Blood. 2006;108(10):
3520-9.
33. Han SY, Kato H, Kato S, Suzuki T, Shibata H,
Ishii S, et al. Functional evaluation of PTEN
missense mutations using in vitro phospho-
inositide phosphatase assay. Cancer Res.
2000;60(12):3147-51.
34. Roman-Gomez J, Jimenez-Velasco A, Agirre
X, Prosper F, Heiniger A, Torres A. Lack of
CpG island methylator phenotype defines a
clinical subtype of T-cell acute lymphoblastic
leukemia associated with good prognosis. J
Clin Oncol. 2005;23(28):7043-9.
35. Sadeq V, Isar N, Manoochehr T. Association
of sporadic breast cancer with
PTEN/MMAC1/TEP1 promoter hyperme-
thylation. Med Oncol. 2011;28(2):420-3.
36. Salvesen HB, Stefansson I, Kretzschmar EI,
Gruber P, MacDonald ND, Ryan A, et al.
Significance of PTEN alterations in endome-
trial carcinoma: a population-based study of
mutations, promoter methylation and PTEN
protein expression. Int J Oncol. 2004;25(6):
1615-23.
37. Carpten JD, Faber AL, Horn C, Donoho GP,
Briggs SL, Robbins CM, et al. A transforming
mutation in the pleckstrin homology domain
of AKT1 in cancer. Nature. 2007;448(7152):
439-44.
38. Chan SM, Weng AP, Tibshirani R, Aster JC,
Utz PJ. Notch signals positively regulate
activity of the mTOR pathway in T-cell
acute lymphoblastic leukemia. Blood.
2007;110(1):278-86.
39. Chiang MY, Xu L, Shestova O, Histen G,
L'Heureux S, Romany C, et al. Leukemia-
associated NOTCH1 alleles are weak tumor
initiators but accelerate K-ras-initiated
leukemia. J Clin Invest. 2008;118(9):3181-94.
40. Weng AP, Millholland JM, Yashiro-Ohtani Y,
Arcangeli ML, Lau A, Wai C, et al. c-Myc is
an important direct target of Notch1 in T-cell
acute lymphoblastic leukemia/lymphoma.
Genes Dev. 2006;20(15):2096-109.
41. Imai T, Tokunaga A, Yoshida T, Hashimoto
M, Mikoshiba K, Weinmaster G, et al. The
neural RNA-binding protein Musashi1 trans-
lationally regulates mammalian numb gene
expression by interacting with its mRNA.
Mol Cell Biol. 2001;21(12):3888-900.
42. Agrawal S, Eng C. Differential expression of
novel naturally occurring splice variants of
PTEN and their functional consequences in
Cowden syndrome and sporadic breast can-
cer. Hum Mol Genet. 2006;15(5):777-87.
43. Teresi RE, Zbuk KM, Pezzolesi MG, Waite
KA, Eng C. Cowden syndrome-affected
patients with PTEN promoter mutations
demonstrate abnormal protein translation.
Am J Hum Genet. 2007;81(4):756-67.
44. Buxbaum JD, Cai G, Chaste P, Nygren G,
Goldsmith J, Reichert J, et al. Mutation
screening of the PTEN gene in patients with
autism spectrum disorders and macro-
cephaly. Am J Med Genet B Neuropsychiatr
Genet. 2007;144B(4):484-91.
45. Poliseno L, Salmena L, Zhang J, Carver B,
Haveman WJ, Pandolfi PP. A coding-indepen-
dent function of gene and pseudogene
mRNAs regulates tumour biology. Nature.
2010;465(7301):1033-8.
46. Salmena L, Carracedo A, Pandolfi PP. Tenets
of PTEN tumor suppression. Cell. 2008;133
(3):403-14.
47. Silva A, Yunes JA, Cardoso BA, Martins LR,
Jotta PY, Abecasis M, et al. PTEN posttrans-
lational inactivation and hyperactivation of
the PI3K/Akt pathway sustain primary T cell
leukemia viability. J Clin Invest. 2008;118
(11):3762-74.
48. Medyouf H, Gao X, Armstrong F, Gusscott S,
Liu Q, Gedman AL, et al. Acute T-cell
leukemias remain dependent on Notch sig-
naling despite PTEN and INK4A/ARF loss.
Blood. 2010;115(6):1175-84.
PTEN and AKT aberrations in pediatric T-ALL
haematologica | 2012; 97(9) 1413
©F
rra
ta 
St
ort
i F
ou
n
a i
n
